Hims & Hers Health, Inc. (NYSE: HIMS) are trading lower Thursday. The U.S. Food and Drug Administration (FDA) issued a new decision regarding the status of tirzepatide injection shortages, which have ...

Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...

Hims & Hers Health Inc (NYSE:HIMS) stock is sitting out the broad market rally today, last seen down 8.4% to trade at $26.15. The personalized healthcare company -- a key player in the weight loss ...

Analyst Allen Lutz of Bank of America Securities maintained a Sell rating on Hims & Hers Health (HIMS – Research Report), retaining the price target of $18.00. Discover top-rated stocks from ...

Hims & Hers Health (NYSE:HIMS) is rewriting the telehealth playbook while its competitors scramble. With a 200% YTD surge, the company's diversified approachcombining virtual consultations, over ...

Hims & Hers (HIMS) is down -12.0%, or -$3.42 to $25.13. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks ...

Morgan Stanley began coverage on shares of Hims & Hers Health (NYSE:HIMS – Free Report) in a report released on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $ ...

Hims & Hers Health (NYSE: HIMS) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a growth stock investors should watch, which Travis Hoium explains in ...

Geode Capital Management LLC increased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 12.7% during the 3rd quarter, according to its most recent 13F filing with ...

Hims & Hers Health (NYSE:HIMS) is rewriting the telehealth playbook while its competitors scramble. With a 200% YTD surge, the company's diversified approachcombining virtual consultations, ...